0 10 Peripheral peripheral JJ 11 16 blood blood NN 17 28 mononuclear mononuclear JJ 29 34 cells cell NNS 35 43 isolated isolate VBN 44 48 from from IN 49 57 patients patient NNS 58 62 with with IN 63 71 diabetic diabetic JJ 72 83 nephropathy nephropathy NN 84 88 show show VBP 89 98 increased increase VBN 99 109 activation activation NN 110 112 of of IN 113 116 the the DT 117 133 oxidative-stress oxidative-stress NN 134 143 sensitive sensitive JJ 144 157 transcription transcription NN 158 164 factor factor NN 165 174 NF-kappaB nf-kappab NN 174 175 . . . 177 186 Increased increase VBN 187 196 oxidative oxidative JJ 197 203 stress stress NN 204 207 and and CC 208 218 subsequent subsequent JJ 219 229 activation activation NN 230 232 of of IN 233 236 the the DT 237 250 transcription transcription NN 251 257 factor factor NN 258 267 NF-kappaB NF-kappaB NNP 268 271 has have VBZ 272 276 been be VBN 277 283 linked link VBN 284 286 to to TO 287 290 the the DT 291 302 development development NN 303 305 of of IN 306 310 late late JJ 311 319 diabetic diabetic JJ 320 333 complications complication NNS 333 334 . . . 335 337 To to TO 338 347 determine determine VB 348 355 whether whether IN 356 365 oxidative oxidative JJ 366 372 stress stress NN 373 382 dependent dependent JJ 383 392 NF-kappaB NF-kappaB NNP 393 403 activation activation NN 404 406 is be VBZ 407 414 evident evident JJ 415 417 in in IN 418 426 patients patient NNS 427 431 with with IN 432 440 diabetic diabetic JJ 441 452 nephropathy nephropathy NN 453 455 we we PRP 456 460 used use VBD 461 463 an an DT 464 479 Electrophoretic electrophoretic JJ 480 488 Mobility Mobility NNP 489 494 Shift Shift NNP 495 500 Assay Assay NNP 501 506 based based JJ 507 523 semiquantitative semiquantitative JJ 524 533 detection detection NN 534 540 system system NN 541 546 which which WDT 547 554 enabled enable VBD 555 557 us us PRP 558 560 to to TO 561 570 determine determine VB 571 580 NF-kappaB NF-kappaB NNP 581 591 activation activation NN 592 594 in in IN 595 597 ex ex FW 598 602 vivo vivo FW 603 611 isolated isolate VBN 612 622 peripheral peripheral JJ 623 628 blood blood NN 629 640 mononuclear mononuclear JJ 641 646 cells cell NNS 646 647 . . . 648 650 We we PRP 651 659 examined examine VBD 660 662 33 33 CD 663 671 patients patient NNS 672 676 with with IN 677 685 diabetes diabetes NN 686 694 mellitus mellitus NN 695 696 ( ( ( 696 700 Type type NN 701 702 I i CD 703 706 and and CC 707 711 Type Type NNP 712 714 II ii CD 714 715 ) ) ) 715 716 . . . 717 725 Patients patient NNS 726 730 with with IN 731 739 diabetic diabetic JJ 740 751 nephropathy nephropathy NN 752 758 showed show VBD 759 765 higher high JJR 766 775 NF-kappaB NF-kappaB NNP 776 783 binding binding NN 784 792 activity activity NN 793 795 in in IN 796 811 Electrophoretic electrophoretic JJ 812 820 Mobility Mobility NNP 821 826 Shift Shift NNP 827 833 Assays Assay NNPS 834 837 and and CC 838 846 stronger strong JJR 847 865 immunohistological immunohistological JJ 866 874 staining staining NN 875 878 for for IN 879 888 activated activate VBN 889 901 NF-kappaBp65 nf-kappabp65 NN 902 906 than than IN 907 915 patients patient NNS 916 923 without without IN 924 929 renal renal JJ 930 943 complications complication NNS 943 944 . . . 945 954 NF-kappaB NF-kappaB NNP 955 962 binding binding NN 963 971 activity activity NN 972 982 correlated correlate VBD 983 987 with with IN 988 991 the the DT 992 998 degree degree NN 999 1001 of of IN 1002 1013 albuminuria albuminuria NN 1014 1015 ( ( ( 1015 1016 r r NN 1017 1018 = = SYM 1019 1024 0.316 0.316 CD 1024 1025 ) ) ) 1026 1029 and and CC 1030 1034 with with IN 1035 1049 thrombomodulin thrombomodulin NN 1050 1056 plasma plasma NN 1057 1071 concentrations concentration NNS 1072 1073 ( ( ( 1073 1074 r r NN 1075 1076 = = SYM 1077 1081 0.33 0.33 CD 1081 1082 ) ) ) 1082 1083 , , , 1084 1094 indicative indicative JJ 1095 1098 for for IN 1099 1110 albuminuria albuminuria NN 1111 1121 associated associated JJ 1122 1133 endothelial endothelial JJ 1134 1145 dysfunction dysfunction NN 1145 1146 . . . 1147 1149 In in IN 1150 1151 a a DT 1152 1153 3 3 CD 1154 1157 day day NN 1158 1170 intervention intervention NN 1171 1176 study study NN 1177 1179 in in IN 1180 1185 which which WDT 1186 1189 600 600 CD 1190 1192 mg mg NN 1193 1195 of of IN 1196 1199 the the DT 1200 1211 antioxidant antioxidant JJ 1212 1220 thioctic thioctic JJ 1221 1225 acid acid NN 1226 1227 ( ( ( 1227 1239 alpha-lipoic alpha-lipoic JJ 1240 1244 acid acid NN 1244 1245 ) ) ) 1246 1249 per per IN 1250 1253 day day NN 1254 1258 were be VBD 1259 1264 given give VBN 1265 1267 to to TO 1268 1272 nine nine CD 1273 1281 patients patient NNS 1282 1286 with with IN 1287 1295 diabetic diabetic JJ 1296 1307 nephropathy nephropathy NN 1308 1317 oxidative oxidative JJ 1318 1324 stress stress NN 1325 1327 in in IN 1328 1334 plasma plasma NN 1335 1342 samples sample NNS 1343 1346 was be VBD 1347 1356 decreased decrease VBN 1357 1359 by by IN 1360 1362 48 48 CD 1362 1363 % % NN 1364 1367 and and CC 1368 1377 NF-kappaB NF-kappaB NNP 1378 1385 binding binding NN 1386 1394 activity activity NN 1395 1397 in in IN 1398 1400 ex ex FW 1401 1405 vivo vivo FW 1406 1414 isolated isolate VBN 1415 1425 peripheral peripheral JJ 1426 1431 blood blood NN 1432 1443 mononuclear mononuclear JJ 1444 1449 cells cell NNS 1450 1452 by by IN 1453 1455 38 38 CD 1455 1456 % % NN 1456 1457 . . . 1458 1460 In in IN 1461 1471 conclusion conclusion NN 1471 1472 , , , 1473 1483 activation activation NN 1484 1486 of of IN 1487 1490 the the DT 1491 1504 transcription transcription NN 1505 1511 factor factor NN 1512 1521 NF-kappaB nf-kappab NN 1522 1524 in in IN 1525 1527 ex ex FW 1528 1532 vivo vivo FW 1533 1541 isolated isolate VBN 1542 1552 peripheral peripheral JJ 1553 1558 blood blood NN 1559 1570 mononuclear mononuclear JJ 1571 1576 cells cell NNS 1577 1579 of of IN 1580 1588 patients patient NNS 1589 1593 with with IN 1594 1602 diabetes diabetes NN 1603 1611 mellitus mellitus NN 1612 1622 correlates correlate VBZ 1623 1627 with with IN 1628 1631 the the DT 1632 1638 degree degree NN 1639 1641 of of IN 1642 1650 diabetic diabetic JJ 1651 1662 nephropathy nephropathy NN 1662 1663 . . . 1664 1673 NF-kappaB NF-kappaB NNP 1674 1684 activation activation NN 1685 1687 is be VBZ 1688 1690 at at IN 1691 1696 least least JJS 1697 1699 in in IN 1700 1704 part part NN 1705 1714 dependent dependent JJ 1715 1717 on on IN 1718 1727 oxidative oxidative JJ 1728 1734 stress stress NN 1735 1740 since since IN 1741 1749 thioctic thioctic JJ 1750 1754 acid acid NN 1755 1756 ( ( ( 1756 1768 alpha-lipoic alpha-lipoic JJ 1769 1773 acid acid NN 1773 1774 ) ) ) 1775 1782 reduced reduce VBD 1783 1792 NF-kappaB NF-kappaB NNP 1793 1800 binding binding NN 1801 1809 activity activity NN 1809 1810 . . .